Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy
Valentina Burgio(Vita-Salute San Raffaele University), Andrea Casadei‐Gardini(Vita-Salute San Raffaele University), Luca Aldrighetti(Vita-Salute San Raffaele University), Massimo Colombo(University of Milan), Francesca Salani(Scuola Superiore Sant'Anna), Emiliano Tamburini(Ospedale Infermi di Rimini), Margherita Rimini(University of Modena and Reggio Emilia), Francesco De Cobelli(Vita-Salute San Raffaele University), Ciro Celsa(Hammersmith Hospital), Silvia Catanese(University of Pisa), Giuseppe Cabibbo(University of Palermo), Fabio Piscaglia(Policlinico S.Orsola-Malpighi), Francesca Ratti(Collaborative Group (United States)), Raffaella Tortora, Stefano Cascinu(University of Modena and Reggio Emilia), Claudia Campani(University of Florence), Claudia Angela Maria Fulgenzi(Università Campus Bio-Medico), Sara Lonardi(Istituto Oncologico Veneto), Carmelo Marco Giacchetto(Collaborative Group (United States)), Mariangela Bruccoleri(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Gianluca Masi(Ospedale di Livorno), Fabio Conti, Caterina Soldà(Istituto Oncologico Veneto), A. Forgione(Azienda USL di Bologna), Fabio Marra(University of Florence), G.G. Di Costanzo, Massimo Iavarone(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Antonio Pellino(University of Padua), Marianna Silletta(Università Campus Bio-Medico), Angelo Della Corte(Vita-Salute San Raffaele University), Federica Pedica(Vita-Salute San Raffaele University), Pietro Lampertico(University of Milan), Massimo Viola(Leiden University), Carmine Coppola, Gabriele Rancatore(Collaborative Group (United States)), Daniela Caterina Amoruso, Francesco Giuseppe Foschi
Cited by 38
Related Papers
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2022|1.4k
Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest
|Journal of Clinical Oncology|2007|1.2k